WASHINGTON – Most Medicare recipients will have access to prescription plans next year that limit their copays for insulin to no more than $35 a month, potentially saving hundreds of dollars, the Trump administration announced Tuesday.
The new benefit — to be formally unveiled at a Rose Garden event Tuesday afternoon — is being touted as a major accomplishment by Trump administration officials eager to change the subject from the grim drumbeat of coronavirus pandemic news.
Older adults who pick a drug plan offering the new insulin benefit would save an estimated $446 a year, while gaining the ability to budget out-of-pocket costs at a manageable amount.